Anthony Amabile, MD
Internal Medicine · Virginia Beach, VANPI 1669445078
Payments from drug & device makers
Across 520 payments — averaging $16.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Novo Nordisk$966
- Boehringer Ingelheim$932
- Amgen$923
- Lilly USA, LLC$547
- Pfizer$463
- plus $3K from 31 others
What the payments were for
- Food & beverage$8,529100%
- Education$110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 103 | $1,838 |
| Novo Nordisk | 65 | $966 |
| Boehringer Ingelheim | 59 | $932 |
| Amgen | 54 | $923 |
| Lilly USA, LLC | 37 | $547 |
| Pfizer | 30 | $463 |
| Novartis | 25 | $428 |
| Sanofi-aventis U.S. LLC | 20 | $278 |
| Johnson & Johnson | 19 | $237 |
| AbbVie(2 entities) | 13 | $231 |
| Abbott | 4 | $198 |
| Amarin Pharma, Inc. | 12 | $141 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $140 |
| GSK | 8 | $126 |
| Dexcom, Inc. | 6 | $102 |
| Exact Sciences | 5 | $100 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $98 |
| Corcept Therapeutics | 4 | $91 |
| Eisai Inc. | 3 | $76 |
| Insulet Corporation | 5 | $76 |
| Merck | 4 | $70 |
| Astellas Pharma US Inc | 4 | $69 |
| Esperion Therapeutics, Inc. | 3 | $60 |
| Kowa Pharmaceuticals America, Inc. | 4 | $54 |
| Supernus Pharmaceuticals, Inc. | 4 | $53 |
| Phathom Pharmaceuticals, Inc. | 2 | $44 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $26 |
| Stryker | 1 | $26 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Grifols USA, LLC | 1 | $19 |
| Antares Pharma, Inc. | 1 | $18 |
| Alnylam Pharmaceuticals Inc. | 1 | $18 |
| Cashflow Solutions, LLC | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Neotract Inc. | 1 | $14 |
| Shire North American Group Inc | 1 | $14 |
| Hikma Pharmaceuticals USA | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AMPLATZER Occluders$144
- Repatha$121
- NURTEC ODT$113
How this compares
$8,540 in reported general payments places this provider in the 90th percentile of 2,724 internal medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 173 | $293,830 |
| JardianceEmpagliflozin | 87 | $123,160 |
| EliquisApixaban | 131 | $117,996 |
| FarxigaDapagliflozin Propanediol | 106 | $110,800 |
| Repatha SureclickEvolocumab | 42 | $52,570 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 41 | $37,660 |
| TrulicityDulaglutide | 19 | $33,237 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 33 | $33,073 |
| JanuviaSitagliptin Phosphate | 18 | $28,000 |
| EntrestoSacubitril/Valsartan | 27 | $27,593 |
| Repatha SyringeEvolocumab | 27 | $21,341 |
| XareltoRivaroxaban | 20 | $19,983 |
| WegovySemaglutide | 11 | $14,598 |
| Tresiba Flextouch U-100Insulin Degludec | 19 | $13,857 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 14 | $13,071 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Wegovy | $966 | $308,428184 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta | $1,838 | $149,199151 claims |
| Boehringer IngelheimJardiance | $932 | $123,16087 claims |
| PfizerEliquis | $463 | $117,996131 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $126 | $50,73255 claims |
| MerckJanuvia, Janumet Xr, Belsomra | $70 | $41,55541 claims |
| Lilly USA, LLCTrulicity | $547 | $33,23719 claims |
| NovartisEntresto | $428 | $27,59327 claims |
| Johnson & JohnsonXarelto | $237 | $19,98320 claims |
| Esperion Therapeutics, Inc.Nexlizet | $60 | $11,94821 claims |
| AbbVieSynthroid | $231 | $7,442113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,724 internal medicine providers in Virginia.
Other internal medicine in Virginia Beach
- Garfield SamuelsVirginia Beach$124K
- Anita KumarVirginia Beach$72K
- Leroy VaughanRichmond$20.8M
- James ClarkCharlottesville$16.2M
- Nabil AndrawisBurke$8.5M
- Mary BlumbergNorfolk$6.5M
- David RamstadSuffolk$5.8M
- Andrew PoklepovicRichmond$4.6M
- Nashwa GabraBurke$4.3M
- Michael DevittCharlottesville$3.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.